Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

Nov. 13, 2024 /PRNewswire/ — TileDB, the database designed for scientific discovery, announced today it is now utilized by 50% of the top 20 global pharmaceutical companies, including industry giant ...

Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company ...

Ingelheim: Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...